Clinical Trial: Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers

U.S., Oct. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07864701) titled 'Study of JMBI-001 in Patients With MYC-Positive Advanced Cancers' on Sept. 22.

Brief Summary: Evaluate the safety and tolerability of JMBI-001 in adults with MYC-positive advanced cancers.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Advance Solid Tumors Lymphoma, Non-Hodgkin

Intervention: DRUG: JMBI-001 Tablets

JMBI-001 will be administered orally once daily on an empty stomach for 4 consecutive days, followed by 3 days without treatment, in repeated 21-day treatment cycles. Dose levels will be determined according to the study protocol.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Chengdu Anticance...